KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $514.1 million.

  • Ionis Pharmaceuticals' Non-Current Assets rose 3998.62% to $514.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 1922.29%. This contributed to the annual value of $383.4 million for FY2024, which is 1009.88% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Non-Current Assets stood at $514.1 million for Q3 2025, which was up 3998.62% from $408.0 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Non-Current Assets registered a high of $514.1 million during Q3 2025, and its lowest value of $258.7 million during Q2 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $348.2 million (2023), whereas its average is $334.0 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Non-Current Assets crashed by 5361.67% in 2021 and then skyrocketed by 3998.62% in 2025.
  • Ionis Pharmaceuticals' Non-Current Assets (Quarter) stood at $266.6 million in 2021, then increased by 24.21% to $331.2 million in 2022, then increased by 5.14% to $348.2 million in 2023, then increased by 10.1% to $383.4 million in 2024, then soared by 34.09% to $514.1 million in 2025.
  • Its last three reported values are $514.1 million in Q3 2025, $408.0 million for Q2 2025, and $394.0 million during Q1 2025.